Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer (NCT01613950) | Novartis Pharmaceuticals | 2012-12-01 |
Track Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein automatically
Every clearance here is in the API, with alerts when new ones post.